Long-Acting Broncho-Dilators: Time for a Re-think

Costello J.F. Sympathomimetic enantiomers in the treatment of asthma. Nashville: Parthenon, 1995

Crane J. , Pearce N. , Flatt A. . Prescribed fenoterol and death from asthma in New Zealand, 1981–83: case-control study. Lancet 1989; i: 917–22

Castle W. , Fuller R. , Hall J. , Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306: 1034–7

Nelson H.S. , Weiss S.T. , Bleecker E.R. , Yancey S.W. , Dorinsky PM ; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 1: 15–26

Lurie P. , Wolfe S.M. Misleading data analyses in salmeterol (SMART) study. Lancet 2005; 366: 1261–2

Dahl R. , Chuchalin A. , Gor D. , Yoxall S. , Sharma R. EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma. Resp Med 2006; 100: 1152–62

Bisgaard H. , Szefler S. Long-acting beta2 agonists and paediatric asthma. Lancet 2006; 367: 287–8

Martinez F.D. Safety of long-acting beta-agonists—an urgent need to clear the air. N Eng J Med 2006; 353: 2637–9

Wilson A.M. , Dempsey O.J. , Sims E.J. , Lipworth B.J. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest 2001; 119: 1021–26

Shah L. , Wilson A.J. , Gibson P.G. , Coughlan J. Long-acting beta2-agonists versus theophyllines for maintenance treatment of asthma. Cochrane Database System Rev 2006; Issue 2

Vakil D.V. , Ayiomamitis A. , Nizami R.M. Use of ipratropium aerosol in the long-term management of asthma. J Asthma 1985; 22: 165–70